BeOne Medicines
Yuan Liu is a seasoned professional in the pharmaceutical research sector, currently serving as a Senior Principal Investigator at BeiGene since November 2021, where responsibilities include leading new therapeutic area strategies and evaluating technologies for R&D. Prior experience includes supporting business development and asset evaluation at Curon Biopharmaceutical, as well as successfully filing IND approvals and leading discovery projects in various roles, including Project Leader and Senior Investigator. A background in analytical solutions was established at Primera Analytical Solutions, along with foundational research in cell biology and pharmacology during time at Genentech and Rutgers University, where Yuan Liu completed a PhD in Cellular & Molecular Pharmacology. Liu also contributed as a bilingual interpreter and has been involved in multiple research projects regarding disease mechanisms, demonstrating a strong commitment to advancing therapeutic development.
This person is not in any teams
This person is not in any offices
BeOne Medicines
36 followers
BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of more than 11,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them.